[go: up one dir, main page]

WO2008020435A3 - Compositions and methods for treatment of mood disorders - Google Patents

Compositions and methods for treatment of mood disorders Download PDF

Info

Publication number
WO2008020435A3
WO2008020435A3 PCT/IL2007/001013 IL2007001013W WO2008020435A3 WO 2008020435 A3 WO2008020435 A3 WO 2008020435A3 IL 2007001013 W IL2007001013 W IL 2007001013W WO 2008020435 A3 WO2008020435 A3 WO 2008020435A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
pharmaceutical composition
compound
relates
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2007/001013
Other languages
French (fr)
Other versions
WO2008020435A2 (en
Inventor
Ayelet Chajut
Tatiana Fuchs
Hagar Kalinsky
Sylvia Kachalsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Publication of WO2008020435A2 publication Critical patent/WO2008020435A2/en
Anticipated expiration legal-status Critical
Publication of WO2008020435A3 publication Critical patent/WO2008020435A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to one or more inhibitors, in particular compounds which down-regulate the expression of a gene selected from the group consisting of ABAT; ADRB1; ADRB3; ARHGEF9; ARRB1; ATP1A1; CACNB4; CAMK2A; CAMK2D; CBLN1; CDH22; CDK5R1; CHN1; CTSD; DDN; DRD3; DUSP6; ENPP1; ENPP2; EPHA4; GABRA1; GMFG; GPM6A; GPNMB; GPR23; HAPLN4; IGF2; IGFBP2; KCNA1; KIF5A; MAPK10; MEF2C; NAPB; NOS1; NPTX2; NRGN; NTS; NUCB1; PCP4; PDCD2; PDE4D; PENK; PHCA; PJA2; PLP1; PMCH; PVALB; QDPR; RPN1; SLC17A7; SLC28A2; SLC8A1; SNAP91; SYN2; SYT1; TKT; TPT1; UGT8 and VIP. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a subject comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
PCT/IL2007/001013 2006-08-15 2007-08-14 Compositions and methods for treatment of mood disorders Ceased WO2008020435A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83809706P 2006-08-15 2006-08-15
US60/838,097 2006-08-15

Publications (2)

Publication Number Publication Date
WO2008020435A2 WO2008020435A2 (en) 2008-02-21
WO2008020435A3 true WO2008020435A3 (en) 2009-05-07

Family

ID=39082444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/001013 Ceased WO2008020435A2 (en) 2006-08-15 2007-08-14 Compositions and methods for treatment of mood disorders

Country Status (1)

Country Link
WO (1) WO2008020435A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444983B2 (en) 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2701846A1 (en) * 2007-10-04 2009-04-09 Bart De Strooper Extracellular targets for alzheimer's disease
GB0808834D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB0808833D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB0808832D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
US8580493B2 (en) 2009-06-08 2013-11-12 Vib Vzw Screening for compounds that modulate GPR3-mediated beta-arrestin signaling and amyloid beta peptide generation
EP2652136B1 (en) * 2010-12-17 2018-11-07 INSERM - Institut National de la Santé et de la Recherche Médicale Nucleic acids targeting tctp for use in the treatment of chemo-or hormone-resistant cancers
EP2797632A1 (en) 2012-01-01 2014-11-05 QBI Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2015148582A1 (en) 2014-03-25 2015-10-01 Arcturus Therapeutics, Inc. Transthyretin allele selective una oligomers for gene silencing
JP6752151B2 (en) * 2014-03-25 2020-09-09 アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． UNA oligomer with reduced OFF-TARGET effect in gene silencing
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
EP3177292B1 (en) 2014-08-07 2020-11-25 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
US10222386B2 (en) 2014-09-19 2019-03-05 The Johns Hopkins University Biomarkers of congnitive dysfunction
EP3277289A4 (en) 2015-04-01 2018-12-05 Arcturus Therapeutics, Inc. Therapeutic una oligomers and uses thereof
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC EXOSOME FOR THE OUTPUT OF THERAPEUTIC ACTIVE SUBSTANCES
EP4036234A1 (en) * 2017-07-17 2022-08-03 Vib Vzw Screening method for synaptogyrin-3 inhibitors
SG11202007652UA (en) 2018-02-21 2020-09-29 Bristol Myers Squibb Co Camk2d antisense oligonucleotides and uses thereof
WO2021016474A1 (en) * 2019-07-23 2021-01-28 Fundación Ciencia Para La Vida (Fcv) Ibd therapy by inhibition of drd3 in regulatory t cells
CN116096899A (en) 2020-06-29 2023-05-09 Ionis制药公司 Compounds and methods for modulating PLP1
CA3190481A1 (en) * 2020-08-04 2022-02-10 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting plp1 expression
EP4247259A4 (en) * 2020-11-18 2024-10-16 Indiana University Research and Technology Corporation METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, CORRESPONDING TO EXISTING AND NEW DRUGS METHODS FOR USING DRUGS AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS
CN112972652B (en) * 2021-03-04 2022-12-16 上海市精神卫生中心（上海市心理咨询培训中心） Application of insulin-like growth factor binding protein 2 in the preparation of drugs against mental disorders caused by early life stress
CN116271051B (en) * 2023-05-16 2023-08-11 山东大学 Application of Phactr4 inhibitor in preparation of depression treatment drugs
CN118878662A (en) * 2024-09-03 2024-11-01 北京大学第六医院 Polypeptide and its application, kit and its application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REYNOLDS ET AL.: "Rational siRNA design for RNA interference.", NATURE BIOTECHNOLOGY., vol. 22, no. 3, March 2004 (2004-03-01), pages 326 - 330, XP002311429, DOI: doi:10.1038/nbt936 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444983B2 (en) 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
US9993567B2 (en) 2009-03-23 2018-06-12 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases

Also Published As

Publication number Publication date
WO2008020435A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008020435A3 (en) Compositions and methods for treatment of mood disorders
Denham Exercise and epigenetic inheritance of disease risk
Choi et al. CRISPR technologies for the treatment of Duchenne muscular dystrophy
Lo et al. Genetic and epigenetic control of gene expression by CRISPR–Cas systems
Duarte et al. The emerging role of MitomiRs in the pathophysiology of human disease
Khan et al. CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases
Giuliani et al. Mitochondrial (Dys) function in inflammaging: do MitomiRs influence the energetic, oxidative, and inflammatory status of senescent cells?
Selle et al. CRISPR‐Based technologies and the future of food science
JP2019524150A5 (en)
HRP20190825T1 (en) Nuclease-mediated regulation of gene expression
Lettieri-Barbato et al. MicroRNAs, long non-coding RNAs, and circular RNAs in the redox control of cell senescence
Xin et al. Application of the genome editing tool CRISPR/Cas9 in non-human primates
JP2017532955A5 (en)
JP2011522036A5 (en)
Locatelli et al. Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside
Dorset et al. The p53 challenge of hematopoietic stem cell gene editing
Zhang et al. MicroRNAs as big regulators of neural stem/progenitor cell proliferation, differentiation and migration: a potential treatment for stroke
Poole et al. Mitochondrial disorders: disease mechanisms and therapeutic approaches
Luo et al. Mitochondrial-related microRNAs and their roles in cellular senescence
Walia et al. Murine models of osteosarcoma: a piece of the translational puzzle
Song et al. Mitochondrial diseases and mtDNA editing
Khouzam et al. CRISPR-Cas9 applications in cardiovascular disease
Spencer et al. 340. Development of a Nuclease Screen to Improve Cas9 Targeting Specificity
Chao et al. Promising therapeutic aspects in human genetic imprinting disorders
WO2019028246A3 (en) Methods of treating genetic hearing loss

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07790065

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07790065

Country of ref document: EP

Kind code of ref document: A2